Roflumilast Foam 0.3% Secures Major FDA Approval to Treat Seborrheic Dermatitis
The foam formulation and once-daily application of roflumilast foam 0.3%, the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades, makes it a favorable alternative to existing treatments.
Express Scripts Adds Cyltezo to National Preferred Formulary
The news comes almost 2 weeks after Cyltezo’s entrance into the US biosimilars market as the first commercially available and FDA-approved interchangeable adalimumab biosimilar.
Cyltezo Biosimilar Now Available in United States
Boehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.
Boxed Warnings Should Not Inhibit Use of All JAK Inhibitors for AD
Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.
FDA: Roflumilast Foam NDA Accepted for Seborrheic Dermatitis
The expected PDUFA date is December 16, 2023.
FDA Accepts Verrica's Resumbitted NDA for VP-102
VP-102 hopes to treat molluscum contagiosum, pending approval from FDA
Plaque Psoriasis Nonsteroidal Treatment Options
Linda Stein Gold, MD explains in nonsteroidal treatment options for plaque psoriasis.
Adolescent Skin Disease and Mental Health: The Psychosocial and Social Media Impact
The relationship between dermatology and social media was analyzed in a poster presentation during SBS 2023 in Miami, Florida.
What's New in Alopecia Areata Management
Natasha A. Mesinkovska, MD, PhD, shares what’s new in alopecia areata management.
New Approaches in Psoriasis and Psoriatic Arthritis Treatment
Understanding the relationship between psoriasis and psoriatic arthritis can help.
A Study of Immune Checkpoint Inhibitors and Complication Rates
Immune checkpoint inhibitor therapy does not appear to increase complication
rates in patients undergoing dermatologic procedures.
BLA Submitted for Lebrikizumab Atopic Dermatitis Treatment
BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.
Examining the Safety and Efficacy of Oral Zinc and Low-Dose Isotretinoin for Acne Vulgaris
Numerous adverse effects are associated with standard-dose isotretinoin.
Skin Sensitivity Reported by 71% of Adults
State of Skin Sensitivity Report raises awareness of the causes of skin sensitivity and its effect on the mind.
Congenital Ichthyosis Treatment TMB-001 Yields Positive Results in 2b Trial
Timber Pharmaceuticals’ CONTROL study evaluated the safety and efficacy of the topical isotretinoin.
FDA Approves Ustekinumab for Treating Psoriatic Arthritis in Children
Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.
Roflumilast Cream 0.3% Approved by FDA for Plaque Psoriasis
Arcutis Biotherapeutics’ roflumilast cream will provide relief to patients aged 12 years or older diagnosed with plaque psoriasis.
FDA Approves Ruxolitinib Cream 1.5% to Treat Nonsegmental Vitiligo
Ruxolitinib (Opzelura) cream is the first and only FDA-approved treatment for patients with vitiligo.
Positive Results Seen with Nutraceutical Supplement for Hair Growth in Women
Perimenopausal, menopausal, and postmenopausal women experienced a progressive improvement in hair growth, shedding, quality of life, and menopausal symptoms after 12 months with an active nutraceutical supplement.
2 Commerce Drive Cranbury, NJ 08512